Yousif Capital Management LLC decreased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 1.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,769 shares of the medical research company's stock after selling 29 shares during the period. Yousif Capital Management LLC's holdings in Bio-Rad Laboratories were worth $1,155,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. SeaCrest Wealth Management LLC bought a new stake in shares of Bio-Rad Laboratories during the second quarter worth $26,000. Private Trust Co. NA grew its position in Bio-Rad Laboratories by 230.0% in the third quarter. Private Trust Co. NA now owns 66 shares of the medical research company's stock valued at $28,000 after purchasing an additional 46 shares in the last quarter. Atlas Capital Advisors LLC bought a new position in Bio-Rad Laboratories in the second quarter valued at $50,000. Allworth Financial LP grew its position in Bio-Rad Laboratories by 414.8% in the third quarter. Allworth Financial LP now owns 139 shares of the medical research company's stock valued at $58,000 after purchasing an additional 112 shares in the last quarter. Finally, Sentry Investment Management LLC grew its position in Bio-Rad Laboratories by 16.5% in the second quarter. Sentry Investment Management LLC now owns 148 shares of the medical research company's stock valued at $73,000 after purchasing an additional 21 shares in the last quarter. Institutional investors own 64.35% of the company's stock.
Get
Bio-Rad Laboratories alerts:
Bio-Rad Laboratories Stock Performance
Shares of BIO stock opened at $470.88 on Friday. The stock has a market cap of $14.04 billion, a P/E ratio of -2.33 and a beta of 0.92. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.50 and a quick ratio of 4.30. The company has a fifty day moving average price of $432.84 and a two-hundred day moving average price of $447.07. Bio-Rad Laboratories, Inc. has a one year low of $344.63 and a one year high of $670.61.
Analyst Upgrades and Downgrades
BIO has been the subject of a number of analyst reports. TheStreet downgraded shares of Bio-Rad Laboratories from a "c" rating to a "d+" rating in a research report on Thursday, October 27th. Royal Bank of Canada assumed coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, December 6th. They issued an "outperform" rating and a $565.00 target price for the company. Credit Suisse Group cut their price target on shares of Bio-Rad Laboratories from $715.00 to $640.00 and set an "outperform" rating for the company in a research note on Friday, October 28th. Finally, StockNews.com cut shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Wednesday, January 18th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $651.25.
Bio-Rad Laboratories Company Profile
(Get Rating)
Bio-Rad Laboratories, Inc engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments.
See Also
- Get a free copy of the StockNews.com research report on Bio-Rad Laboratories (BIO)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
